Point State Capital LP Neurocrine Biosciences Inc Transaction History

Point State Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $476,783 - $602,382	-6,600 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $457,446 - $604,098	6,600 New	6,600 $581,000
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $6.42 Million - $8.17 Million	-64,900 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $4.89 Million - $6.88 Million	64,900 New	64,900 $6.38 Million

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.